Írland - enska - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - duloxetine - gastro-resistant capsule, hard - 60 milligram(s) - antidepressants - psychoanaleptics; other antidepressants - treatment of major depressive disorder. treatment of diabetic peripheral neuropathic pain. treatment of generalised anxiety disorder.

Írland - enska - HPRA (Health Products Regulatory Authority)

rowex ltd - duloxetine hydrochloride - gastro-resistant capsule - 30 milligram(s) - other antidepressants; duloxetine

Írland - enska - HPRA (Health Products Regulatory Authority)

rowex ltd - duloxetine hydrochloride - gastro-resistant capsule - 60 milligram(s) - other antidepressants; duloxetine

Írland - enska - HPRA (Health Products Regulatory Authority)

teva b.v. - duloxetine hydrochloride - gastro-resistant capsule, hard - 30 milligram(s) - antidepressants

Írland - enska - HPRA (Health Products Regulatory Authority)

teva b.v. - duloxetine hydrochloride - gastro-resistant capsule, hard - 60 milligram(s) - antidepressants

Írland - enska - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - acetylsalicylic acid - gastro-resistant tablet - 75 milligram(s) - platelet aggregation inhibitors excl. heparin; acetylsalicylic acid

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - ustekinumab, quantity: 135 mg - injection, solution - excipient ingredients: histidine hydrochloride monohydrate; sucrose; polysorbate 80; methionine; disodium edetate; water for injections; histidine - crohn?s disease,stelara is indicated for the treatment of adult patients with moderately to severely active crohn?s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a tnf alpha antagonist or have medical contraindications to such therapies.,ulcerative colitis,stelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - ustekinumab, quantity: 90 mg - injection, solution - excipient ingredients: histidine hydrochloride monohydrate; sucrose; water for injections; polysorbate 80; histidine - plaque psoriasis,adults - stelara is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.,paediatric population, 6 years and older - stelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from 6 years of age who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,psoriatic arthritis (psa),stelara, alone or in combination with methotrexate, is indicated for the treatment of signs and symptoms of active psoriatic arthritis in adult patients (18 years and older) where response to previous non-biological dmard therapy has been inadequate.,crohn?s disease,stelara is indicated for the treatment of adult patients with moderately to severely active crohn?s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a tnf alpha antagonist or have medical contraindications to such therapies.,ulcerative colitis,stelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; purified talc; silicon dioxide; sodium starch glycollate; stearic acid; iron oxide red; carmellose sodium; carnauba wax; magnesium stearate; titanium dioxide; macrogol 6000; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - ustekinumab, quantity: 45 mg - injection, solution - excipient ingredients: histidine; polysorbate 80; histidine hydrochloride monohydrate; water for injections; sucrose - plaque psoriasis,adults - stelara is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.,paediatric population, 6 years and older - stelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from 6 years of age who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,psoriatic arthritis (psa),stelara, alone or in combination with methotrexate, is indicated for the treatment of signs and symptoms of active psoriatic arthritis in adult patients (18 years and older) where response to previous non-biological dmard therapy has been inadequate.,crohn?s disease,stelara is indicated for the treatment of adult patients with moderately to severely active crohn?s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a tnf alpha antagonist or have medical contraindications to such therapies.,ulcerative colitis,stelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.